Friday, August 09, 2019 10:43:03 AM
You can chalk it up however you want --corruption, bureaucracy, incompetence-- this was a game changer and I could tell from Thero's opening line last night.
Amarin knew that something was up when they did the FOIA request. I am 100% certain that there is a well sponsored campaign by very influential people to detail Amarin.
One can opine how it began (moron at mom's basement) but it spiraled into something huge. Just think, Amarin FOIA'ed FDA for communication with clown Nissen -- does Thero wear a tinfoil hat too?
What is most bothersome to me is not who the perpetrators are (could have been anyone) but the fact that the FDA actually drank the koolaid and may drink it again after November 14.
And this is stunning, it still has not been updated:
https://www.fda.gov/advisory-committees/advisory-committee-calendar
Yet, FDA did not want Amarin to PR it. Imagine today, stock tanking and us running around like chickens with heads cut off, guessing for the reason.
Again, at this point it irrelevant to me if its corruption, bureaucracy or incompetence. Walking into AdCom and expecting a fair process would be suicidal. There will be these gotcha questions which will be impossible to answer and Amarin will be ambushed, regardless of how near perfect their data is.
Fact is, the data is not perfect, its 99.99% perfect, but if the FDA wanted to derail Amarin's chances, they could. This could be done with literally any trial.
Amarin knew that something was up when they did the FOIA request. I am 100% certain that there is a well sponsored campaign by very influential people to detail Amarin.
One can opine how it began (moron at mom's basement) but it spiraled into something huge. Just think, Amarin FOIA'ed FDA for communication with clown Nissen -- does Thero wear a tinfoil hat too?
What is most bothersome to me is not who the perpetrators are (could have been anyone) but the fact that the FDA actually drank the koolaid and may drink it again after November 14.
And this is stunning, it still has not been updated:
https://www.fda.gov/advisory-committees/advisory-committee-calendar
Yet, FDA did not want Amarin to PR it. Imagine today, stock tanking and us running around like chickens with heads cut off, guessing for the reason.
Again, at this point it irrelevant to me if its corruption, bureaucracy or incompetence. Walking into AdCom and expecting a fair process would be suicidal. There will be these gotcha questions which will be impossible to answer and Amarin will be ambushed, regardless of how near perfect their data is.
Fact is, the data is not perfect, its 99.99% perfect, but if the FDA wanted to derail Amarin's chances, they could. This could be done with literally any trial.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
